RxDoctor Payments Data

Sandra Uzzalino

Family · Pompton Plains, NJNPI 1124078043

Payments from drug & device makers

$1,937in general payments, 2019–2025

Across 105 payments — averaging $18.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$273
  • Novo Nordisk$255
  • Biohaven Pharmaceutical Holding Company Ltd.$152
  • Amgen$151
  • Phathom Pharmaceuticals, Inc.$141
  • Idorsia Pharmaceuticals US Inc$123
  • plus $842 from 19 others

What the payments were for

  • Food & beverage$1,937100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,937 in reported general payments places this provider in the 85th percentile of 2,692 family providers in New Jersey.

See all family providers in New Jersey

Medicare billing

Part B allowed, 2024
$4,322
Medicare patients
30
Services billed
51

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide31$40,434
EliquisApixaban23$26,373
JardianceEmpagliflozin26$20,577
MounjaroTirzepatide11$18,774
FarxigaDapagliflozin Propanediol15$14,518
JanuviaSitagliptin Phosphate16$13,426
VascepaIcosapent Ethyl15$7,500
XareltoRivaroxaban12$6,603
SynthroidLevothyroxine Sodium42$3,130
Omega-3 Acid Ethyl Esters20$2,624
Rosuvastatin Calcium164$2,144
Atorvastatin Calcium156$1,974
Telmisartan45$1,926
Levothyroxine Sodium144$1,584
Metoprolol Succinate92$1,544

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$255$40,43431 claims
PfizerEliquis$18$26,37323 claims
Boehringer IngelheimJardiance$29$20,57726 claims
Lilly USA, LLCMounjaro$117$18,77411 claims
MerckJanuvia$62$13,42616 claims
Johnson & JohnsonXarelto$83$6,60312 claims
AbbVieSynthroid$273$3,13042 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,692 family providers in New Jersey.

Other family in Pompton Plains

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →